256 related articles for article (PubMed ID: 14534333)
1. First-trimester screening for trisomies 21 and 18.
Wapner R; Thom E; Simpson JL; Pergament E; Silver R; Filkins K; Platt L; Mahoney M; Johnson A; Hogge WA; Wilson RD; Mohide P; Hershey D; Krantz D; Zachary J; Snijders R; Greene N; Sabbagha R; MacGregor S; Hill L; Gagnon A; Hallahan T; Jackson L;
N Engl J Med; 2003 Oct; 349(15):1405-13. PubMed ID: 14534333
[TBL] [Abstract][Full Text] [Related]
2. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
5. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
6. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
[TBL] [Abstract][Full Text] [Related]
7. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
8. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH
Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343
[TBL] [Abstract][Full Text] [Related]
9. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
10. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
[TBL] [Abstract][Full Text] [Related]
11. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.
Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST
Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021
[TBL] [Abstract][Full Text] [Related]
13. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
Audibert F; Gagnon A; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
15. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
16. Screening for Down's syndrome--too many choices?
Mennuti MT; Driscoll DA
N Engl J Med; 2003 Oct; 349(15):1471-3. PubMed ID: 14534341
[No Abstract] [Full Text] [Related]
17. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
18. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
19. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
20. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.
Gil MM; Revello R; Poon LC; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jan; 47(1):45-52. PubMed ID: 26498918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
